EVALUATION OF IN VITRO ANTICANCER ACTIVITY OF SYMPLOCOS RACEMOSA BARK AGAINST HEPATOCELLULAR CARCINOMA

Authors

  • Niyati S. Acharya Department of Pharmacognosy, Institute of Pharmacy, Nirma University, Ahmedabad 382481
  • Unnati R. Shah Pioneer Pharmacy Degree College
  • Ripal G. Shah Sun Pharmaceutical Advanced Research Center
  • Sanjeev Acharya Nirma University
  • Lal Hingorani Pharmanza Herbal Pvt. Ltd

Keywords:

Symplocos racemosa, Hepatocellular carcinoma, Cytotoxicity, Hep3B, MTT assay

Abstract

Objective: To investigate in vitro anticancer activity of different extracts of bark of Symplocos racemosa against hepatocellular carcinoma.

Methods: Different successive extracts of Symplocos racemosa bark were prepared using hexane, chloroform, ethyl acetate, n-butanol and water and were tested in vitro for cytotoxicity using (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay in rat normal liver cells (BRL-3A) and human hepatocellular carcinoma (Hep3B) cells.

Results: Ethyl acetate and chloroform extract of Symplocos racemosa exhibited cytotoxicity against human hepatocellular carcinoma (Hep3B) cells in vitro with IC50 value (µg/ml) of 63.45 and 75.55 respectively and not affected the normal liver (BRL-3A) cells.

Conclusion: Symplocos racemosa bark extracts showed potential cytotoxic effects on human hepatocellular carcinoma cells. The anticancer activity exhibited by ethyl acetate and chloroform extract might be due to presence of phenolics and flavonoid constituents present in the bark. Ethyl acetate extract can further be explored for possible cytotoxic activity using in vivo models of liver cancer.

 

Downloads

Download data is not yet available.

References

Wang S, Penchala S, Prabhu S, Wang J, Huang Y. Molecular basis of traditional chinese medicine in cancer chemoprevention. Curr Drug Discovery Technol 2010;7:67-75.

Sreelatha S, Jeyachirta A, Padma PR. Antiproliferation and induction of apoptosis by Moringa oleiafera extract on human cancer cells. Food Chem Toxicol 2011;49:1270-5.

Shah U, Shah R, Acharya S, Acharya N. Novel anticancer agents from plant sources. Chin J Nat Med 2013;11:16-23.

Ibrahim B, Sowemimo A, Spies L, Koekomoer T, Venter M, Odukoya O. Antiproliferative and apoptosis inducing activity of Markhamia tomentosa leaf extract on Hela cells. J Ethnopharmacol 2013;149:745-9.

Kirtikar KR, Basu BD. Indian Medicinal Plants. 2nded. Dehradun: International Book Distributors; 1975.

Nadkarni KM. Indian Materia Medica. 3rded. Mumbai: Ramdas Bhatkal for Popular Prakashan Pvt. Ltd; 2002.

Ali M, Bhutani KK, Srivastava TN. Triterpenoids from Symplocos racemosa bark. Phytochem 1990; 29:3601-04.

Dash B, Kashyap L. Diagnosis and treatment of Galaganda, Gandamala, Apaci, granthi and arbuda. Diagnosis and treatment of diseases in Ayurveda. New Delhi: Concept Publishing Company; 1987.

Singhal GD, Singh LM. The management of glandular swellings, cervical lymphadenopathy, tumours and goiters. Operative considerations in ancient Indian surgery based on Susruta Samhita, Chikitsa sthana. Varanasi: Singhal Publications; 1982.

Murthy KRS. Bhavaprakasa of Bhavamisra. Vol. II. Varanasi: Krishnadas Academy; 2001.

Singh P, Singh R, Gupta LN, Kumar N. Lodhra: A single remedy for different ailments. Int J Pharm Boil Sci Arch 2015;6:1-7.

Anonymous. The Ayurvedic Pharmacopoeia of India. 1sted. Vol. I. Government of India, New Delhi; 2001.

Nagore DH, Bhusnar HU, Nipanikar SU. Phytopharmacological profile of Symplocos racemosa: a review. Pharmacologia 2014;5:76-83.

Cory AH, Owen TC, Barltrop JA, Cory JG. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 1991;3:207-12.

Published

01-11-2015

How to Cite

Acharya, N. S., U. R. Shah, R. G. Shah, S. Acharya, and L. Hingorani. “EVALUATION OF IN VITRO ANTICANCER ACTIVITY OF SYMPLOCOS RACEMOSA BARK AGAINST HEPATOCELLULAR CARCINOMA”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 7, no. 11, Nov. 2015, pp. 384-5, https://journals.innovareacademics.in/index.php/ijpps/article/view/8123.

Issue

Section

Short Communication(s)